医学部
Profile Information
- Affiliation
- Fujita Health University
- Degree
- 医学博士(慶應義塾大学)
- Other name(s) (e.g. nickname)
- https://bantane.fujita-hu.ac.jp/department/obstericians.html
- J-GLOBAL ID
- 200901012107446377
- researchmap Member ID
- 5000096026
- External link
日本産科婦人科学会 産婦人科専門医
日本産科婦人科学会 産婦人科指導医
日本生殖医学会認定 生殖医療専門医
日本生殖医学会認定 生殖医療指導医
日本婦人科腫瘍学会 婦人科腫瘍専門医
日本婦人科腫瘍学会 婦人科腫瘍指導医
日本がん治療認定医機構 がん治療認定医
日本がん治療認定医機構 暫定教育医
Research Interests
14Research Areas
1Research History
15-
Apr, 2023 - Present
-
Apr, 2020 - Mar, 2023
-
Mar, 2019 - Mar, 2023
-
Oct, 2018 - Mar, 2023
-
Apr, 2008 - Mar, 2023
Education
2-
1995 - 1999
Committee Memberships
5-
May, 2012
-
2011
-
2011
-
2009
Awards
5-
2013
-
2009
-
2008
-
2008
-
2004
Major Papers
60-
Nature Communications, 5(448) 1-9, Jul 22, 2014 Peer-reviewed© 2014 Macmillan Publishers Limited. All rights reserved. Endometriosis is a common gynaecological disease associated with pelvic pain and infertility. Current treatments include oral contraceptives combined with nonsteroidal anti-inflammatory drugs or surgery to remove lesions, all of which provide a temporary but not complete cure. Here we identify an endometriosis-targeting peptide that is internalized by cells, designated z13, using phage display. As most endometriosis occurs on organ surfaces facing the peritoneum, we subtracted a phage display library with female mouse peritoneum tissue and selected phage clones by binding to human endometrial epithelial cells. Proteomics analysis revealed the z13 receptor as the cyclic nucleotide-gated channel β3, a sorting pathway protein. We then linked z13 with an apoptosis-inducing peptide and with an endosome-escaping peptide. When these peptides were co-administered into the peritoneum of baboons with endometriosis, cells in lesions selectively underwent apoptosis with no effect on neighbouring organs. Thus, this study presents a strategy that could be useful to treat peritoneal endometriosis in humans.
-
Proc. Natl. Acad. Sci. USA (PNAS), 108(49) 19587-92, Dec 6, 2011 Peer-reviewedAlthough numerous carbohydrates play significant roles in mammalian cells, carbohydrate-based drug discovery has not been explored due to the technical difficulty of chemically synthesizing complex carbohydrate structures. Previously, we identified a series of carbohydrate mimetic peptides and found that a 7-mer peptide, designated I-peptide, inhibits hematogenous carbohydrate-dependent cancer cell colonization. During analysis of the endothelial surface receptor for I-peptide, we found that I-peptide bound to annexin 1 (Anxa1). Because Anxa1 is a highly specific tumor vasculature surface marker, we hypothesized that an I-peptide-like peptide could target anticancer drugs to the tumor vasculature. This study identifies IFLLWQR peptide, designated IF7, as homing to tumors. When synthetic IF7 peptide was conjugated to fluorescent Alexa 488 (A488) and injected intravenously into tumor-bearing mice, IF7-A488 targeted tumors within minutes. IF7 conjugated to the potent anticancer drug SN-38 and injected intravenously into nude mice carrying human colon HCT116 tumors efficiently suppressed tumor growth at low dosages with no apparent side effects. These results suggest that IF7 serves as an efficient drug delivery vehicle by targeting Anxa1 expressed on the surface of tumor vasculature. Given its extremely specific tumor-targeting activity, IF7 may represent a clinically relevant vehicle for anticancer drugs.
-
Proc. Natl. Acad. Sci. USA (PNAS), 106(9) 3095-100, Mar 3, 2009 Peer-reviewedCell surfaces of epithelial cancer are covered by complex carbohydrates, whose structures function in malignancy and metastasis. However, the mechanism underlying carbohydrate-dependent cancer metastasis has not been defined. Previously, we identified a carbohydrate-mimicry peptide designated I-peptide, which inhibits carbohydrate-dependent lung colonization of sialyl Lewis X-expressing B16-FTIII-M cells in E/P-selectin doubly-deficient mice. We hypothesized that lung endothelial cells express an unknown carbohydrate receptor, designated as I-peptide receptor (IPR), responsible for lung colonization of B16-FTIII-M cells. Here, we visualized IPR by in vivo biotinylation, which revealed that the major IPR is a group of 35-kDa proteins. IPR proteins isolated by I-peptide affinity chromatography were identified by proteomics as Ser/Arg-rich alternative pre-mRNA splicing factors or Sfrs1, Sfrs2, Sfrs5, and Sfrs7 gene products. Bacterially expressed Sfrs1 protein bound to B16-FTIII-M cells but not to parental B16 cells. Recombinant Sfrs1 protein bound to a series of fucosylated oligosaccharides in glycan array and plate-binding assays. When anti-Sfrs antibodies were injected intravenously into mice, antibodies labeled a subset of lung capillaries. Anti-Sfrs antibodies inhibited homing of I-peptide-displaying phage to the lung colonization of B16-FTIII-M cells in vivo in the mouse. These results strongly suggest that Sfrs proteins are responsible for fucosylated carbohydrate-dependent lung metastasis of epithelial cancers.
-
Proc. Natl. Acad. Sci. USA (PNAS), 104(10) 3799-804, Mar 6, 2007 Peer-reviewedDuring human embryo implantation, trophectoderm mediates adhesion of the blastocyst to the uterine epithelium. The rapid growth of the embryo and invasion of the maternal tissue suggest adhesion-induced activation of the embryonal cells. We show here that ligation of trophinin, a homophilic cell adhesion molecule expressed on trophoblastic cells, induces tyrosine phosphorylation in trophinin-expressing trophoblastic HT-H cells. The phosphorylation could be induced in HT-H cells with the binding of trophinin-expressing cells or anti trophinin antibodies. Trophinin-dependent tyrosine phosphorylation was associated with actin reorganization. We also isolated trophinin-binding peptides from phage libraries. These peptides exhibited the consensus sequence GWRQ and seemed to reproduce the effects of trophinin-mediated cell adhesion. Upon binding of a GWRQ peptide, HT-H cells became highly proliferative and motile. HT-H cells expressed ErbB family receptors and bound EGF and heparin-binding EGF-like growth factor (HB-EGF), but ErbB family receptor phosphorylation in these cells required GWRQ. In the absence of GWRQ, trophinin interacted with the cytoplasmic protein bystin, which binds to ErbB4 and blocks its autophosphorylation. In HT-H cells, GWRQ peptide dissociated trophinin from bystin, and ErbB4 was activated. Culturing monkey blastocysts in the presence of the peptide increased total number and motility of the trophectoderm cells. These results suggest that trophinin-mediated cell adhesion functions as a molecular switch for trophectoderm activation in human embryo implantation.
-
Science, 295(5552) 124-7, Jan 4, 2002 Peer-reviewedSpermatogenesis is a precisely regulated process in which the germ cells closely interact with Sertoli cells. The molecular basis of this cell-cell adhesion is unknown. Here, we demonstrate that targeted disruption of Man2a2, a gene encoding alpha-mannosidase IIx (MX), an enzyme that forms intermediate asparagine-linked carbohydrates (N-glycans), results in Man2a2 null males that are largely infertile. The Man2a2 null spermatogenic cells fail to adhere to Sertoli cells and are prematurely released from the testis to epididymis. We identified an N-glycan structure that plays a key role in germ cell-Sertoli cell adhesion and showed that a specific carbohydrate was required for spermatogenesis.
-
Nature cell biology, 4(1) 73-8, Jan, 2002 Peer-reviewedThe Ras-related small GTPase RalA is involved in controlling actin cytoskeletal remodelling and vesicle transport in mammalian cells. We identified the mammalian homologue of Sec5, a subunit of the exocyst complex determining yeast cell polarity, as a specific binding partner for GTP-ligated RalA. Inhibition of RalA binding to Sec5 prevents filopod production by tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 (IL-1) and by activated forms of RalA and Cdc42, signalling intermediates downstream of these inflammatory cytokines. We propose that the RalA-exocyst complex interaction integrates the secretory and cytoskeletal pathways.
Misc.
40-
Biochemistry and biophysics reports, 22(22) 100740-100740, Jul, 2020 Peer-reviewed
-
British Journal of Cancer (Nature Publishing Group ), 2020 Peer-reviewed<title>Abstract</title> <sec> <title>Background</title> Annexin A1 is expressed specifically on the tumour vasculature surface. Intravenously injected IF7 targets tumour vasculature via annexin A1. We tested the hypothesis that IF7 overcomes the blood–brain barrier and that the intravenously injected IF7C(RR)-SN38 eradicates brain tumours in the mouse. </sec> <sec> <title>Methods</title> (1) A dual-tumour model was generated by inoculating luciferase-expressing melanoma B16 cell line, B16-Luc, into the brain and under the skin of syngeneic C57BL/6 mice. IF7C(RR)-SN38 was injected intravenously daily at 7.0 μmoles/kg and growth of tumours was assessed by chemiluminescence using an IVIS imager. A similar dual-tumour model was generated with the C6-Luc line in immunocompromised SCID mice. (2) IF7C(RR)-SN38 formulated with 10% Solutol HS15 was injected intravenously daily at 2.5 μmoles/kg into two brain tumour mouse models: B16-Luc cells in C57BL/6 mice, and C6-Luc cells in nude mice. </sec> <sec> <title>Results</title> (1) Daily IF7C(RR)-SN38 injection suppressed tumour growth regardless of cell lines or mouse strains. (2) Daily injection of Solutol-formulated IF7C(RR)-SN38 led into complete disappearance of B16-Luc brain tumour in C57BL/6 mice, whereas this did not occur in C6-Luc in nude mice. </sec> <sec> <title>Conclusions</title> IF7C(RR)-SN38 crosses the blood–brain barrier and suppresses growth of brain tumours in mouse models. Solutol HS15-formulated IF7C(RR)-SN38 may have promoted an antitumour immune response. </sec>
-
Nutrition and cancer, 71(2) 312-319, Mar, 2019 Peer-reviewed
-
European journal of gynaecological oncology, 39(5) 838-842, Jan, 2018 Peer-reviewed
Books and Other Publications
12Presentations
6Works
4-
2014 Othershttp://www.natureasia.com/ja-jp/ncomms/abstracts/55462
Major Research Projects
22-
基盤研究(C), Apr, 2023 - Mar, 2026
-
基盤研究(B), Apr, 2019 - Mar, 2023
-
AMED橋渡し研究シーズA, 2019 - 2020
-
挑戦的萌芽研究, Apr, 2015 - Mar, 2018
-
基盤研究(B), Apr, 2015 - Mar, 2018
-
基盤研究(B), Apr, 2012 - Mar, 2015
-
挑戦的萌芽研究, Apr, 2012 - Mar, 2015
-
基盤研究(B), Apr, 2011 - Mar, 2014
-
知財活用促進ハイウェイ, 科学技術振興機構(JST), Apr, 2012 - Mar, 2013
-
基盤研究(B), Apr, 2009 - Mar, 2012
-
基盤研究(B), Apr, 2008 - Mar, 2011
-
上原記念生命科学財団
-
高松宮妃癌研究助成基金
-
創薬支援ネットワーク(日本版NIH)→AMED(日本医療研究開発機構)